JP2020534362A - 成人における焦点てんかんの処置のための合成経皮的カンナビジオール - Google Patents

成人における焦点てんかんの処置のための合成経皮的カンナビジオール Download PDF

Info

Publication number
JP2020534362A
JP2020534362A JP2020537297A JP2020537297A JP2020534362A JP 2020534362 A JP2020534362 A JP 2020534362A JP 2020537297 A JP2020537297 A JP 2020537297A JP 2020537297 A JP2020537297 A JP 2020537297A JP 2020534362 A JP2020534362 A JP 2020534362A
Authority
JP
Japan
Prior art keywords
cbd
effective amount
seizures
frequency
seizure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020537297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020534362A5 (enExample
Inventor
ガターマン，ドナ
セブリー，テリ
スミス，テッド
メッセンハイマー，ジョン
Original Assignee
ジナーバ・ファーマシューティカルズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジナーバ・ファーマシューティカルズ・インコーポレイテッド filed Critical ジナーバ・ファーマシューティカルズ・インコーポレイテッド
Publication of JP2020534362A publication Critical patent/JP2020534362A/ja
Publication of JP2020534362A5 publication Critical patent/JP2020534362A5/ja
Priority to JP2023145851A priority Critical patent/JP7650929B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020537297A 2017-09-19 2018-09-18 成人における焦点てんかんの処置のための合成経皮的カンナビジオール Pending JP2020534362A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023145851A JP7650929B2 (ja) 2017-09-19 2023-09-08 成人における焦点てんかんの処置のための合成経皮的カンナビジオール

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201762560446P 2017-09-19 2017-09-19
US62/560,446 2017-09-19
US201762593575P 2017-12-01 2017-12-01
US62/593,575 2017-12-01
US201862613160P 2018-01-03 2018-01-03
US62/613,160 2018-01-03
US201862652995P 2018-04-05 2018-04-05
US62/652,995 2018-04-05
US201862660198P 2018-04-19 2018-04-19
US62/660,198 2018-04-19
PCT/IB2018/057189 WO2019058261A1 (en) 2017-09-19 2018-09-18 TRANSDERMAL SYNTHETIC CANNABIDIOL FOR THE TREATMENT OF FOCAL EPILEPSY IN ADULTS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023145851A Division JP7650929B2 (ja) 2017-09-19 2023-09-08 成人における焦点てんかんの処置のための合成経皮的カンナビジオール

Publications (2)

Publication Number Publication Date
JP2020534362A true JP2020534362A (ja) 2020-11-26
JP2020534362A5 JP2020534362A5 (enExample) 2021-10-28

Family

ID=63762572

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020537297A Pending JP2020534362A (ja) 2017-09-19 2018-09-18 成人における焦点てんかんの処置のための合成経皮的カンナビジオール
JP2023145851A Active JP7650929B2 (ja) 2017-09-19 2023-09-08 成人における焦点てんかんの処置のための合成経皮的カンナビジオール

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023145851A Active JP7650929B2 (ja) 2017-09-19 2023-09-08 成人における焦点てんかんの処置のための合成経皮的カンナビジオール

Country Status (11)

Country Link
US (4) US20190083388A1 (enExample)
EP (1) EP3684411A1 (enExample)
JP (2) JP2020534362A (enExample)
KR (1) KR20200055067A (enExample)
AU (1) AU2018337933A1 (enExample)
BR (1) BR112020004947A2 (enExample)
CA (1) CA3075719A1 (enExample)
IL (2) IL301910A (enExample)
JO (1) JOP20200045A1 (enExample)
MX (2) MX2020003004A (enExample)
WO (1) WO2019058261A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024514843A (ja) * 2021-04-08 2024-04-03 パイク セラピューティクス インコーポレイテッド 発作性疾患を治療するための医薬組成物及び方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3733156A1 (de) * 2019-05-02 2020-11-04 Gábor Fóti C.b.d.m therapie
WO2021055499A1 (en) * 2019-09-17 2021-03-25 Zynerba Pharmaceuticals, Inc. Treatment of behavioral impairment in developmental and epileptic encephalopathy
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
JP2022551730A (ja) 2019-10-14 2022-12-13 パイク セラピューティクス，インコーポレイテッド カンナビジオールの経皮送達
GB2597287A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
US20220047541A1 (en) * 2020-08-17 2022-02-17 Pike Therapeutics, Inc. Pharmaceutical compositions and methods for treating parkinson's disease
AU2021392090A1 (en) * 2020-12-03 2023-07-06 Harmony Biosciences Management, Inc. Cannabidiol for the treatment of refractory seizures

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010127033A1 (en) 2009-04-28 2010-11-04 Alltranz Inc. Formulations of cannabidiol and methods of using the same
PT2473475T (pt) * 2009-08-31 2017-08-02 Zynerba Pharmaceuticals Inc Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas
GB2530001B (en) * 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2539472A (en) * 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) * 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"ZYNERBA PHARMACEUTICALS ANNOUNCES TOP-LINE RESULTS FROM PHASE 2 STAR 1 TRIAL OF ZYN002 IN ADULT EP, JPN6022036755, 17 August 2017 (2017-08-17), ISSN: 0005052225 *
小児内科, vol. 46, no. 9, JPN6022036758, 2014, pages 1332 - 1336, ISSN: 0005052228 *
小児科診療, vol. 78巻, 2号, JPN6022036756, pages 79 - 84, ISSN: 0005052227 *
臨床と研究, vol. 92巻, 6号, JPN6022036757, 2015, pages 743 - 750, ISSN: 0005052226 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024514843A (ja) * 2021-04-08 2024-04-03 パイク セラピューティクス インコーポレイテッド 発作性疾患を治療するための医薬組成物及び方法

Also Published As

Publication number Publication date
KR20200055067A (ko) 2020-05-20
JP2023171776A (ja) 2023-12-05
MX2024002904A (es) 2024-04-04
US20190083388A1 (en) 2019-03-21
JOP20200045A1 (ar) 2020-02-27
CA3075719A1 (en) 2019-03-28
US20250302734A1 (en) 2025-10-02
WO2019058261A1 (en) 2019-03-28
AU2018337933A1 (en) 2020-03-12
US20250213465A1 (en) 2025-07-03
BR112020004947A2 (pt) 2020-09-15
MX2020003004A (es) 2020-11-06
US20210030665A1 (en) 2021-02-04
WO2019058261A9 (en) 2019-07-04
JP7650929B2 (ja) 2025-03-25
IL301910A (en) 2023-06-01
IL272818A (en) 2020-04-30
EP3684411A1 (en) 2020-07-29

Similar Documents

Publication Publication Date Title
JP7650929B2 (ja) 成人における焦点てんかんの処置のための合成経皮的カンナビジオール
JP7590803B2 (ja) 経皮カンナビジオールゲルを用いた変形性関節症の治療方法
JP7570924B2 (ja) 電位依存性カリウムチャネル開口薬のバイオアベイラビリティー及び曝露を高める方法
EP4114466B1 (en) Treatment of pain and vasoconstriction
AU2016255707A1 (en) Uses of cannabidiol for treatment of infantile spasms
US20240009210A1 (en) Cannabidiol for the Treatment of Refractory Seizures
JP2016074728A (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
CN114786660A (zh) 使用mtorc1调节剂的治疗方法
EA028060B1 (ru) Комбинированная терапия бокового амиотрофического склероза
WO2018051355A1 (en) Tamoxifen or tamoxifen in combination with arginine/citrulline for the use in the treatment of muscular dystrophy
CA3076180C (en) Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
EP2727595B1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
KR20230137404A (ko) Cbd를 사용한 수면 무호흡증의 치료
JP2024502466A5 (enExample)
JP7840873B2 (ja) うつ病の治療方法
EA052074B1 (ru) Топическое лечение витилиго ингибитором jak
US20110245212A1 (en) Methods of alleviating the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder
EA044821B1 (ru) Способ увеличения биологической доступности и степени воздействия активатора потенциал-зависимых калиевых каналов

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230509